If you have experienced a heart attack while taking the new anti-clotting drug Pradaxa, you aren’t alone. The following important information will help you understand the evidence suggesting the danger of heart attack associated with Pradaxa:
- A recent Cleveland Clinic study of 30,514 patients has shown that patients being treated with Pradaxa have a 33% higher chance of suffering a heart attack. The study compared patients on Pradaxa with those on its predecessor, Warfarin, as well as patients on a placebo. The noteworthy finding is that Pradaxa is more likely than Warfarin to cause acute coronary syndrome or heart attack.
- While the risk of heart attack alone is only increased by .25% every year as opposed to the Warfarin treatment, when combined with other health problems, this risk quickly becomes very serious.
- FDA investigations are ongoing. Reports of severe bleeding associated with Pradaxa have been unusually numerous, causing countries like Australia and Japan to release statements warning of the safety risk. Doctors have been advised by the European Medicines Agency to check patients’ kidney function before prescribing Pradaxa.
- John Smith, M.D., a spokesperson for the creators of Pradaxa, claims that the Cleveland Clinic study was not well executed. Pradaxa maker Boehringer Ingelheim continues communications with the FDA.
If you or someone you know has suffered a Pradaxa-related heart attack, don’t hesitate to seek legal representation. Contact experienced Pradaxa injury attorneys Gray and White at 1-888-450-4456.